A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease

Neurochemistry International

Volumn 56, Issue 8, 2010, Pages 937-947

  Salek, Reza M ^a   Xia, Jing ^b   Innes, Amy ^d   Sweatman, Brian C ^c   Adalbert, Robert ^b   Randle, Suzanne ^d   McGowan, Eileen ^d   Emson, Piers C ^b   Griffin, Julian L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

1H NMR; Amyloid precursor protein; Animal models; Biomarkers; Metabonomics; Neurodegeneration

Indexed keywords

4 AMINOBUTYRIC ACID; ALANINE; AMYLOID PRECURSOR PROTEIN; BRAIN EXTRACT; CHOLINE; CREATINE; CREATINE PHOSPHATE; FATTY ACID; GLUTAMIC ACID; GLUTAMINE; GLYCINE; ISOLEUCINE; LACTIC ACID; LEUCINE; MUTANT PROTEIN; N ACETYLASPARTIC ACID; PHOSPHORYLCHOLINE; SUCCINIC ACID; TAURINE; VALINE;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; FRONTAL CORTEX; GENE MUTATION; HIPPOCAMPUS; MESENCEPHALON; METABOLOMICS; MOUSE; NONHUMAN; OLFACTORY BULB; PATIENT MONITORING; PONS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; METABOLOME; METABOLOMICS; MICE; MICE, TRANSGENIC;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 77953124257     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.04.001     Document Type: Article

References (75)

1. Adlard P.A., Vickers J.C. Morphologically distinct plaque types differentially affect dendritic structure and organisation in the early and late stages of Alzheimer's disease. Acta Neuropathol. 2002, 103:377-383.
2. 1H MRS at 0.5T. Neurology 2001, 56:737-742.
3. Attwell D. Glia and neurons in dialogue. Nature 1994, 369:707-708.
4. Baslow M.H. N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem. Res. 2003, 28:941-953.
5. Blass J.P. Pathophysiology of the Alzheimer's Syndrome 1993, Lippincott Williams & Wilkins, Hagerstown, MD, pp. S25-S38, ETATS-UNIS.
6. Blass J.P. Metabolic alterations common to neural and non-neural cells in Alzheimer's disease. Hippocampus 1993, 3(Spec No):45-53.
7. Borchelt D.R., Wong P.C., Sisodia S.S., Price D.L. Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis. Brain Pathol. 1998, 8:735-757.
8. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 1991, 82:239-259.
9. Burg M.B., Kwon E.D., Kultz D. Regulation of gene expression by hypertonicity. Annu. Rev. Physiol. 1997, 59:437-455.
10. Chen J.G., Charles H.C., Barboriak D.P., Doraiswamy P.M. Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate. Acta Neurol. Scand. Suppl. 2000, 176:20-26.
11. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
12. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992, 360:672-674.
13. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St George Hyslop P., Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 1997, 3:67-72.
14. Cloarec O., Dumas M.E., Craig A., Barton R.H., Trygg J., Hudson J., Blancher C., Gauguier D., Lindon J.C., Holmes E., Nicholson J. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem 2005, 77:1282-1289.
15. Cruts M., van Duijn C.M., Backhovens H., Van den Broeck M., Wehnert A., Serneels S., Sherrington R., Hutton M., Hardy J., St George-Hyslop P.H., Hofman A., Van Broeckhoven C. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum. Mol. Genet. 1998, 7:43-51.
16. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004, 1012:60-65.
17. Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., Yan Y., Wang C., Zhang H., Molkentin J.D., Gunn-Moore F.J., Vonsattel J.P., Arancio O., Chen J.X., Yan S.D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 2008, 14:1097-1105.
18. Dudal S., Krzywkowski P., Paquette J., Morissette C., Lacombe D., Tremblay P., Gervais F. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol. Aging 2004, 25:861-871.
19. Eriksson L., Johansson E., Kettaneh-Wold N., Wold S. Introduction to Multi- and Megavariate Data Analysis Using Projection Methods (PCA and PLS) 1999, Umetrics, Umea, Sweden.
20. Esposito L., Raber J., Kekonius L., Yan F., Yu G.Q., Bien-Ly N., Puolivali J., Scearce-Levie K., Masliah E., Mucke L. Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J. Neurosci. 2006, 26:5167-5179.
21. Feng G., Mellor R.H., Bernstein M., Keller-Peck C., Nguyen Q.T., Wallace M., Nerbonne J.M., Lichtman J.W., Sanes J.R. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000, 28:41-51.
22. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 1984, 42:1-11.
23. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
24. Garcia-Alloza M., Tsang S.W., Gil-Bea F.J., Francis P.T., Lai M.K., Marcos B., Chen C.P., Ramirez M.J. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiol. Aging 2006, 27:1110-1117.
25. Gibson G.E., Sheu K.F.R., Blass J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm. 1998, 105:855-870.
26. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
27. Govindaraju V., Young K., Maudsley A.A. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000, 13:129-153.
28. Haass C., Lemere C.A., Capell A., Citron M., Seubert P., Schenk D., Lannfelt L., Selkoe D.J. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat. Med. 1995, 1:1291-1296.
29. Hancu I., Zimmerman E.A., Sailasuta N., Hurd R.E. 1H MR spectroscopy using TE averaged PRESS: a more sensitive technique to detect neurodegeneration associated with Alzheimer's disease. Magn. Reson. Med. 2005, 53:777-782.
30. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J. Alzheimers Dis. 2006, 9:151-153.
31. Hardy J., Duff K., Hardy K.G., Perez-Tur J., Hutton M. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci. 1998, 1:355-358.
32. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
33. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
34. Höskuldsson A. Prediction Methods in Science and Technology 1996, Thor Publishing, Copenhagen.
35. Hoyer S. Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. Acta Neurol. Scand. Suppl. 1996, 165:18-24.
36. Hoyer S. Models of Alzheimer's disease: cellular and molecular aspects. J. Neural Transm. Suppl. 1997, 49:11-21.
37. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
38. Huang W., Alexander G.E., Chang L., Shetty H.U., Krasuski J.S., Rapoport S.I., Schapiro M.B. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology 2001, 57:626-632.
39. Hugon J., Vallat J.M., Dumas M. Role of glutamate and excitotoxicity in neurologic diseases. Rev. Neurol. (Paris) 1996, 152:239-248.
40. Huxtable R.J. Taurine in the central nervous system and the mammalian actions of taurine. Prog. Neurobiol. 1989, 32:471-533.
41. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 1997, 56:965-973.
42. Ishii K., Sasaki M., Kitagaki H., Yamaji S., Sakamoto S., Matsuda K., Mori E. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J. Nucl. Med. 1997, 38:925-928.
43. Jackson J.E. A User's Guide to Principal Components 1991, John Wiley, New York.
44. Janus C., Phinney A.L., Chishti M.A., Westaway D. New developments in animal models of Alzheimer's disease. Curr. Neurol Neurosci. Rep. 2001, 1:451-457.
45. Jenkins B.G., Klivenyi P., Kustermann E., Andreassen O.A., Ferrante R.J., Rosen B.R., Beal M.F. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 2000, 74:2108-2119.
46. Jessen F., Traeber F., Freymann N., Maier W., Schild H.H., Heun R., Block W. A comparative study of the different N-acetylaspartate measures of the medial temporal lobe in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2005, 20:178-183.
47. 1H MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. Neurol Res. 2004, 26:488-495.
48. Kanfer J.N., Singh I.N., Pettegrew J.W., McCartney D.G., Sorrentino G. Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell. J. Lipid Mediat. Cell Signal. 1996, 14:361-363.
49. Kantarci K., Xu Y., Shiung M.M., O'Brien P.C., Cha R.H., Smith G.E., Ivnik R.J., Boeve B.F., Edland S.D., Kokmen E., Tangalos E.G., Petersen R.C., Jack C.R. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2002, 14:198-207.
50. Klunk W.E., Xu C.J., Panchalingam K., McClure R.J., Pettegrew J.W. Analysis of magnetic resonance spectra by mole percent: comparison to absolute units. Neurobiol. Aging 1994, 15:133-140.
51. Lanctot K.L., Herrmann N., Rothenburg L., Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer's disease. Int. Psychogeriatr. 2007, 19:151-158.
52. 1H NMR spectroscopy. NMR Biomed. 2002, 15:37-44.
53. Lindon, J.C., Nicholson, J.K., Everett, J.R., 1999. NMR spectroscopy of biofluids, Annual Reports on NMR Spectroscopy, vol. 38, Annual Reports on NMR Spectroscopy, vol. 38, pp. 1-88.
54. Macura S., Huang Y. Two-dimensional chemical exchange and cross-relaxation spectroscopy of coupled nuclear spins. J. Magn. Reson. 1981, 43:259-281.
55. Marjanska M., Curran G.L., Wengenack T.M., Henry P.G., Bliss R.L., Poduslo J.F., Jack C.R., Ugurbil K., Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11906-11910.
56. McGowan E., Eriksen J., Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006, 22:281-289.
57. McIlwain H., Bachelard H.S. Biochemistry and the Central Nervous Systems 1985, Churchill Livingstone, Edinburgh, New York.
58. 1H magnetic resonance spectroscopic imaging. Neurology 1993, 43:509-515.
59. Mohanakrishnan P., Fowler A.H., Vonsattel J.P., Husain M.M., Jolles P.R., Liem P., Komoroski R.A. An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp. Brain Res. 1995, 102:503-510.
60. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
61. 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J. Biol. Chem. 2005, 280:42508-42514.
62. Petroff O.A., Pleban L.A., Spencer D.D. Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of the epileptic human brain. Magn. Reson. Imaging 1995, 13:1197-1211.
63. Pettegrew J.W., Panchalingam K., Moossy J., Martinez J., Rao G., Boller F. Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease. Arch. Neurol. 1988, 45:1093-1096.
64. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E.V., Lim K.O. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch. Gen. Psychiatry 1999, 56:185-192.
65. Rissman R.A., De Blas A.L., Armstrong D.M. GABA(A) receptors in aging and Alzheimer's disease. J. Neurochem. 2007, 103:1285-1292.
66. Rothman D.L., Behar K.L., Hyder F., Shulman R.G. In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu. Rev. Physiol. 2003, 65:401-427.
67. Rubinsztein D.C. The genetics of Alzheimer's disease. Prog. Neurobiol. 1997, 52:447-454.
68. Schousboe A., Westergaard N., Waagepetersen H.S., Larsson O.M., Bakken I.J., Sonnewald U. Trafficking between glia and neurons of TCA cycle intermediates and related metabolites. Glia 1997, 21:99-105.
69. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
70. Selkoe D.J., Wolfe M.S. In search of gamma-secretase: presenilin at the cutting edge. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:5690-5692.
71. 13C NMR spectroscopy. NMR Biomed. 2003, 16:424-429.
72. Suh Y.H., Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 2002, 54:469-525.
73. Svennerholm L., Gottfries C.G. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J. Neurochem. 1994, 62:1039-1047.
74. Wold S., Albano C., Dunn W.J., Edlund U., Esbensen K., Geladi P., Hellberg S., Johansson E., Lindberg W., Sjöström M. Multivariate Data Analysis in Chemistry 1984, D. Reidel Publishing Company, Holland.
75. Woodhouse A., Vickers J.C., Adlard P.A., Dickson T.C. Dystrophic neurites in TgCRND8 and Tg2576 mice mimic human pathological brain aging. Neurobiol. Aging 2009, 30:864-874.